Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Immunotherapy: an emerging modality to checkmate brain metastasis, Molecular Cancer

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Addition of nivolumab, ipilimumab to chemotherapy extends OS in NSCLC with brain metastases

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Decoding molecular programs in melanoma brain metastases

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

MBM - Melanoma Brain Metastases

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combination immunotherapy shrinks metastatic brain cancer